ESMO
Refine Search
Pharmaceutical
The annual congress of the European Society of Medical Oncology (ESMO) will look a lot different this time, but that does not mean the data will be any less imp 4 September 2020
Pharmaceutical
With weeks to go until the virtual annual congress of the European Society of Medical Oncology (ESMO), guidance on the use of next-generation sequencing (NGS) i 24 August 2020
Pharmaceutical
Weeks after receiving US approval for its fourth-line gastrointestinal stromal tumor (GIST) option, Deciphera Pharmaceuticals has presented new data supporting 3 July 2020
Pharmaceutical
For more than a decade, the main area of interest and focus in oncology has been the astonishing progress of immuno-oncology therapies, led lately by the all-co 14 October 2019
Pharmaceutical
In the runup to the annual meeting of the European Society of Medical Oncology (ESMO), one of the more eagerly anticipated presentations focused on former Loxo 4 October 2019
Pharmaceutical
As the dust settles on 2019’s annual meeting of the European Society of Medical Oncology (ESMO), data from several candidates give hope that the burden of disea 4 October 2019
Pharmaceutical
At the annual congress of the European Society of Medical Oncology (ESMO) in Barcelona, rival datasets for Lynparza (olaparib) and Zejula (niraparib) have teed 28 September 2019
Pharmaceutical
North Carolina, USA-based G1 Therapeutics has reported overall survival (OS) data at the European Society of Medical Oncology (ESMO), which suggest trilaciclib 28 September 2019
Biotechnology
US biotech G1 Therapeutics has presented preliminary overall survival (OS) data from its Phase II trial of trilaciclib in combination with chemotherapy for the 28 September 2019
Pharmaceutical
Pivotal data from a Phase II study of the FGFR inhibitor pemigatinib will be used to support a US filing later in the year, says Incyte chief executive Hervé Ho 27 September 2019
Pharmaceutical
This year, the annual congress of the European Society for Medical Oncology (ESMO) is taking place in Barcelona. 25 September 2019
Pharmaceutical
As German pharma major Bayer looks to expand its oncology offering, the latest new data will be presented at the annual meeting of the European Society for Medi 25 September 2019
Pharmaceutical
Merck KGaA has outlined data it will present at the the 2019 European Society for Medical Oncology (ESMO) annual meeting, starting in Barcelona on Friday. 23 September 2019
Biotechnology
Swiss cancer giant Roche has outlined the data it intends to present at the upcoming annual meeting of the European Society for Medical Oncology (ESMO). 23 September 2019
Pharmaceutical
New York’s Pfizer (NYSE: PFE) will present data on 11 therapies in 22 types of cancer, at the European Society for Medical Oncology (ESMO) annual meeting, in Ba 20 September 2019
Biotechnology
Bristol-Myers Squibb has outlined the data it will present at this year’s annual meeting of the European Society for Medical Oncology (ESMO), in Barcelona. 19 September 2019
Pharmaceutical
London-listed drugmaker GlaxoSmithKline will present data across nine tumor types at the upcoming annual meeting of the European Society for Medical Oncology Co 17 September 2019
Pharmaceutical
At the upcoming annual meeting of the European Society for Medical Oncology (ESMO), UK-based drugmaker AstraZeneca will present data in 63 abstracts, including 16 September 2019
Biotechnology
France’s Pierre Fabre and US-based development partner Array BioPharma have announced positive interim analysis results from the Phase III BEACON CRC trial. 8 July 2019
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze